Navigation Links
Halozyme Therapeutics to Present at J.P. Morgan Healthcare Conference on January 12
Date:1/5/2011

SAN DIEGO, Jan. 5, 2011 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced its participation in the 29th Annual J.P. Morgan Healthcare Conference to be held on January 9-13, 2011 in San Francisco. Gregory Frost, Ph.D., president and CEO, will present an overview of Halozyme's business strategy and its product development pipeline on Wednesday, January 12, 2011 at 3:30 p.m. PST (6:30 p.m. EST). To listen to the live webcast or a replay of the presentation, please visit the Investor Relations section of the company's Web site at www.halozyme.com. A replay will be available for 90 days after the event.

(Logo:  http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)

About Halozyme Halozyme Therapeutics is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology and drug delivery markets. The company's product portfolio is based primarily on intellectual property covering the family of human enzymes known as hyaluronidases and additional enzymes that affect the extracellular matrix. Halozyme's Enhanze™ technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. The company has key partnerships with Roche to apply Enhanze technology to Roche's biological therapeutics, including Herceptin® and MabThera®, and with Baxter Bi
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Halozyme Therapeutics Completes Enrollment in Chemophase Phase I/IIa Clinical Trial for Superficial Bladder Cancer
2. Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience With Hylenex
3. Halozyme Therapeutics Presents Pre-Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association for Cancer Research Conference
4. Halozyme Therapeutics Presents Findings on Combinations of rHuPH20 Enzyme With Bisphosphonates at the American Association for Cancer Research Conference
5. Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability
6. Halozyme Therapeutics Announces That Chemophase Meets Primary Endpoint in Phase I/IIa Clinical Trial
7. Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models
8. Halozyme Therapeutics Announces Roche Begins Phase 1 Clinical Trial and Selects Fourth Exclusive Biologic Target
9. Halozyme Therapeutics Begins Phase 1 Clinical Trial of Bisphosphonate Administered With rHuPH20 Enzyme
10. Halozyme Provides HYLENEX® Product Reintroduction Update
11. Halozyme Therapeutics Announces Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... and RALEIGH, N.C. , ... Communications, LLC (CTMC), and Integrated Clinical Trial Services, ... and retention for clinical trials announce that they ... Trial Marketing Services (i-CTMS). i-CTMS will provide a ... to pharmaceutical, biotechnology and medical device companies. ...
(Date:12/15/2014)... Dec. 12, 2014 Research and Markets ... "Inferior Vena Cava (IVC) Filters - Global Trends, ... http://photos.prnewswire.com/prnh/20130307/600769 ... to reach US$435 million by 2016. The ... of the global value while Europe ...
(Date:12/15/2014)... N.J. , Dec. 15, 2014   Regeneron ... and NYSE: SNY) are collaborating with nationally-recognized patient and ... , an awareness program that will gauge how much ... associated with high LDL-C (bad cholesterol).  American adults are ... take a brief poll and answer a few key ...
Breaking Medicine Technology:Integrated Clinical Trial Services and Clinical Trial Marketing Communications Form Joint Venture 2Integrated Clinical Trial Services and Clinical Trial Marketing Communications Form Joint Venture 3Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 2Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 3Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 4Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 2Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 3Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 4Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 5Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 6
... March 6, 2012 Biospace Lab S.A. ... College London will collaborate on the development of novel ... of the Biospace Lab PhotonIMAGER™ Optima pre-clinical imaging platform. ... Dr Mark Lythgoe, and molecular probes, Dr Martin Pule, ...
... GP Strategies Corporation (NYSE: GPX ), ... sales and technical training, e-Learning solutions, management consulting and ... CFO Sharon Esposito-Mayer will speak at the ROTH Capital ... 3:30 p.m. PT. The conference will be held at ...
Cached Medicine Technology:Biospace Lab and the Centre for Advanced Biomedical Imaging at University College London to Collaborate on Development of Novel Real-Time in Vivo Optical Imaging Technologies 2
(Date:12/15/2014)... SIMpalm, a leading mobile app development company ... its client, which allows users to keep track of ... finding the right wine. At the center of ... chemistry and wine information. All this information is assembled ... wines that are close counterparts to one another are ...
(Date:12/15/2014)... HealthDay Reporter FRIDAY, Dec. 12, 2014 (HealthDay ... of American women who have migraine: The debilitating headaches don,t ... association between migraine and breast cancer risk," said lead researcher ... School. "There is no positive association, so there is no ... About 18 percent of American women and 6 percent ...
(Date:12/15/2014)... Kathy McAfee, America's Marketing Motivator, was announced ... the category of Best Blog 2014. McAfee received the ... career blog Networking Ahead which combines many ... their talent and influence through better networking, leadership and ... Networking Ahead for Business, has been motivating readers for ...
(Date:12/15/2014)... 15, 2014 At the leading, long-established ... AutismOne and Focus Autism will welcome ... research on the effects of toxins to children’s health, ... information. , Luminaries such as Dr. Lucija Tomljenovic ... with esteemed, credentialed colleagues of the United States to ...
(Date:12/15/2014)... December 15, 2014 For the second year ... Review “Top 30 Coffees of 2014.” Bird Rock Coffee Roasters’ ... Guji Zone Ethiopia at number 10. This is the first ... Coffee Review’s selection is ranked on quality, value, and other ... scored 96 out of 100, and at $17.99 for 12-ounces, ...
Breaking Medicine News(10 mins):Health News:Use WinMatch Connect App to Keep Track of Wines You Like 2Health News: No Link Between Migraine, Breast Cancer Risk, Study Says 2Health News:Kathy McAfee, America’s Marketing Motivator, Wins Best Blog from Women World Awards 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 3Health News:Bird Rock Coffee Roasters Ranks Second and Tenth in Coffee Review’s ‘Top 30 Coffees of 2014’ 2
... to cardiac rehabilitation, appear to be associated with increased ... a report in the Oct. 13, 2008, issue of ... JAMA/Archives journals. , Emory University researchers studied 639 patients ... heart attack. Six months later, 297 of the patients ...
... benign breast disease, or when tumor was larger , , ... consuming other caffeine-laden foods does not appear to boost ... not appear to be associated with overall risk of ... from the division of preventive medicine, in the department ...
... Quarter 2008 Earnings Conference Call on October 30 - - Presentation at Oppenheimer,s 19th ... ... Analysts on ... November 7 -, SAN DIEGO, Oct. 13 Gen-Probe Incorporated,(Nasdaq: GPRO ) ...
... on women, study found , , MONDAY, Oct. 13 (HealthDay News) ... shrinks, a new study has found. , "The take-home ... to hurt your brain," said Rajesh Miranda, an associate professor ... Science Center College of Medicine. "This is something we knew, ...
... Spine, PLANO, Texas, Oct. 13 In an ... shares "Nine for Your Spine." The,release of these nine ... 2008., National Spine Health Day was established to ... effective means of reducing the,prevalence and severity of back ...
... National Coalition for,Quality Colorectal Cancer Screening and Care ... published September 18 in the New,England Journal of ... need to recognize that CT Colonography is not ... that Colonoscopy,remains the "Gold Standard" for colorectal cancer ...
Cached Medicine News:Health News:Caffeine Consumption Doesn't Raise Overall Breast Cancer Risk 2Health News:Caffeine Consumption Doesn't Raise Overall Breast Cancer Risk 3Health News:Gen-Probe Announces Webcasts of Three Upcoming Investor Events 2Health News:Gen-Probe Announces Webcasts of Three Upcoming Investor Events 3Health News:Excess Drinking Shrinks the Brain 2Health News:Texas Back Institute Announces 'Nine for Your Spine' for National Spine Health Day - October 16 2Health News:Texas Back Institute Announces 'Nine for Your Spine' for National Spine Health Day - October 16 3Health News:National Coalition for Quality Colorectal Cancer Screening and Care Conveys Concerns over CT Colonography 2Health News:National Coalition for Quality Colorectal Cancer Screening and Care Conveys Concerns over CT Colonography 3
...
...
Rhoton Curettes, titanium, length 191 mm, straight....
Sundt Slim-Line Temporary Vessel Clips used for temporary vascular occlusion during intracranial surgical procedures. Non-magnetic, MP35N, MRI compatible, gold color. Bayonet....
Medicine Products: